Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer

Clinical Lung Cancer

Volumn 9, Issue 1, 2008, Pages 51-58

  Cella, David ^a,b   Eton, David ^a,b   Hensing, Thomas A ^a,b   Masters, Gregory A ^c   Parasuraman, Bhash ^d  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HELEN F GRAHAM CANCER CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Disease progression; Functional status; Non small cell lung cancer; Patient reported outcome; Treatment response

Indexed keywords

ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; COUGHING; DISEASE ASSOCIATION; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT ASSESSMENT; SYMPTOM; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION;

EID: 39149130337     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.009     Document Type: Article

References (32)

1. Cooley M. Symptoms in adults with lung cancer: a systematic research review. J Pain Symptom Manage 2000; 19:137-53.
2. Gift AG, Jablonski A, Stommel M, et al. Symptom clusters in elderly patients with lung cancer. Oncol Nurs Forum 2004; 31:202-12.
3. Given BA, Given CW, Sikorskii A, et al. Symptom clusters and physical function for patients receiving chemotherapy. Semin Oncol Nurs 2007; 23:121-6.
4. Butt Z, Webster K, Eisenstein AR, et al. Quality of life in lung cancer: The validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy-Lung scale. Hematol Oncol Clin N Am 2005; 19:389-420.
5. Chang CH, Cella D, Masters GA, et al. Real-time clinical application of quality-of-life assessment in advanced lung cancer. Clin Lung Cancer 2002; 4:104-9.
6. Soni MK, Cella D, Masters GA, et al. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer 2002; 4:153-60.
7. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000; 89:1634-46.
8. Diekmann JM, Engber D, Wassern R. Cancer pain control: one state's experience. Oncol Nurs Forum 1989; 16:219-23.
9. Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to cancer services: A review of barriers to quality care. Cancer 1999; 86:2378-90.
10. Riddell A, Fitch MI. Patients' knowledge of and attitudes toward the management of cancer pain. Oncol Nurs Forum 1997; 24:1775-84.
11. Thomason TE, McCune JS, Bernard SA, et al. Cancer pain survey: Patient-centered issues in control. J Pain Symptom Manage 1998; 15:275-84.
12. Wilkie DJ, Huang HY, Berry DL, et al. Cancer symptom control: Feasibility of a tailored, interactive computerized program for patients. Fam Community Health 2001; 24:48-62.
13. Buxton J, White M, Osoba D. Patients' experiences using a computerized program with a touch-sensitive video monitor for the assessment of health-related quality of life. Qual Life Res 1998; 7:513-9.
14. Carlson LE, Speca M, Hagen N, et al. Computerized quality-of-life screening in a cancer pain clinic. J Palliat Care 2001; 17:46-52.
15. Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology practice: A feasibility study. Eur J Cancer 1998; 34:1181-6.
16. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. J Clin Oncol 2004; 22:714-24.
17. Donnelly S, Walsh D, Rybicki L. The symptoms of advanced cancer: Identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 1995; 11:27-32.
18. Nekolaichuk CL, Bruera E, Spachynski K, et al. A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 1999; 13:311-23.
19. Davis K, Yount S, Del Ciello K, et al. An innovative symptom monitoring tool for people with advanced lung cancer: A pilot demonstration. J Support Oncol 2007; 5:381-7.
20. Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosporamide. J Chron Dis 1960; 11:7-33.
21. Therasse P, Arbuck SG, Eisenharter EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-16.
22. Cella D, Bonomi AE,, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12:199-220.
23. Eton DT, Cella D, Yount SE, et al. Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12). Lung Cancer 2007; 57:339-47.
24. Chang VT, Hwang SS, Feuerman M, et al. Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: A role for symptom assessment. Cancer 2000; 88:1175-83.
25. Grand S, Zech D, Diefenbach C, et al. Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994; 9:372-82.
26. McCorkle R, Quint-Benoliel J. Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease. Soc Sci Med 1983; 17:431-8.
27. Cooley ME, Short TH, Moriarty HJ. Symptom prevalence, distress, and change over time in adults receiving treatment for lung cancer. Psychooncology 2003; 12:694-708.
28. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A:1326-36.
29. Eton DT, Fairclough DL, Cella D, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group study 5592. J Clin Oncol 2003; 21:1536-43.
30. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005; 23:2946-54.
31. Natale RB. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer. Sem Oncol 2004; 31(suppl 9):23-30.
32. Victorson D, Soni M, Cella D. Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer 2006; 106:494-504.